These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26083988)

  • 1. Is the time in therapeutic range using the ratio of tests equivalent to the Rosendaal method?
    Caldeira D; Cruz I; Morgado G; Stuart B; Gomes AC; Martins C; João I; Pereira H
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):972-6. PubMed ID: 26083988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants.
    Carrier M; Kimpton M; Wells PS; Langlois N; Kherani S; Le Gal G
    Blood Coagul Fibrinolysis; 2014 Dec; 25(8):812-5. PubMed ID: 24914740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study.
    Caldeira D; Cruz I; Morgado G; Stuart B; Gomes C; Martins C; João I; Pereira H
    BMC Res Notes; 2014 Dec; 7():891. PubMed ID: 25491419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
    Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H
    Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining time in therapeutic range for busy clinicians: frequency of dose changes is a good surrogate marker to identify patients with suboptimal anticoagulation with warfarin.
    Vijenthira A; Le Gal G; Castellucci LA; Carrier M
    Thromb Res; 2014 Sep; 134(3):584-6. PubMed ID: 25037497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving Anticoagulation Measurement Novel Warfarin Composite Measure.
    Razouki Z; Burgess JF; Ozonoff A; Zhao S; Berlowitz D; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):600-7. PubMed ID: 26420820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients.
    Kooistra HA; Veeger NJ; Khorsand N; Kluin-Nelemans HC; Meijer K; Piersma-Wichers M
    Thromb Haemost; 2015 Apr; 113(4):881-90. PubMed ID: 25518854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldán-Rabadán I; Roldán V; Muñiz J; Raña-Míguez P; Ruiz-Ortiz M; Cequier Á; Bertomeu-Martínez V; Badimón L; Anguita M; Lip GYH; Marín F;
    Europace; 2018 Sep; 20(9):1435-1441. PubMed ID: 29095971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
    Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
    Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
    Singer DE; Hellkamp AS; Yuan Z; Lokhnygina Y; Patel MR; Piccini JP; Hankey GJ; Breithardt G; Halperin JL; Becker RC; Hacke W; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
    J Am Heart Assoc; 2015 Mar; 4(3):e001349. PubMed ID: 25736441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists.
    Ruiz-Ortiz M; Bertomeu V; Cequier Á; Marín F; Anguita M
    Thromb Haemost; 2015 Oct; 114(4):695-701. PubMed ID: 26054407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study.
    Barrios V; Escobar C; Prieto L; Osorio G; Polo J; Lobos JM; Vargas D; García N
    Rev Esp Cardiol (Engl Ed); 2015 Sep; 68(9):769-76. PubMed ID: 26169326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction Score for Anticoagulation Control Quality Among Older Adults.
    Lin KJ; Singer DE; Glynn RJ; Blackley S; Zhou L; Liu J; Dube G; Oertel LB; Schneeweiss S
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28982676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa.
    Mwita JC; Francis JM; Pillay C; Ogah OS; Goshu DY; Agyekum F; Musonda JM; James MC; Tefera E; Kabo T; Ditlhabolo KI; Ndlovu K; Ayodele AY; Mikomangwa WP; Chillo P; Damasceno A; Folson AA; Oyekunle A; Tebuka E; Kalokola F; Forrest K; Dunn H; Karaye K; Jean-Pierre FL; Oljira CF; Assefa T; Taiwo TS; Nwafor CE; Omole O; Anakwue R; Cohen K
    J Thromb Thrombolysis; 2024 Apr; 57(4):613-621. PubMed ID: 38478250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients.
    Lafarge L; Khayi F; Bel-Kamel A; Charhon N; Sarfati L; Falquet B; Ducher M; Bourguignon L
    Drugs Aging; 2018 Jun; 35(6):569-574. PubMed ID: 29882202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment.
    Gorzelak-Pabiś P; Zyzak S; Krewko Ł; Broncel M
    Pol Arch Med Wewn; 2016 Aug; 126(7-8):494-501. PubMed ID: 27511466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
    Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
    Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.
    Barco S; Granziera S; Coppens M; Douxfils J; Nijkeuter M; Riva N; Vanassche T; Zhang G; Lin M; Kamphuisen PW; Cohen AT; Beyer-Westendorf J
    Thromb Haemost; 2019 Apr; 119(4):675-684. PubMed ID: 30731492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.